oxybutynin has been researched along with Chronic Pain in 45 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Chronic Pain: Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effectiveness and tolerability of transdermal buprenorphine (TDB) treatment in real-world setting in Asian patients with musculoskeletal pain." | 9.24 | Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. ( Bin, SI; Chan, SK; Chung, CK; In, Y; Kim, H; Lichauco, JJ; Mok, CC; Moon, H; Moon, YW; Ng, TK; Penserga, EG; Shin, DA; Yoon, DH; You, D, 2017) |
| "This study examines the efficacy of the buprenorphine transdermal system (BTDS) for reducing the interference of pain on physical and emotional functioning associated with chronic low back pain (CLBP)." | 9.20 | Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. ( Lynch, SY; Miller, K; Munera, C; Pergolizzi, JV; Raffa, R; Ripa, SR; Wen, W; Yarlas, A, 2015) |
| "To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks." | 9.17 | Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. ( Brennan, MJ; Dain, B; Lynch, SY; Miller, K; Ripa, SR; Wen, W; Yarlas, A, 2013) |
| "The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients." | 9.16 | Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. ( Apkarian, AV; Baliki, MN; Chanda, ML; Hashmi, JA; Huang, L; Parks, EL; Schnitzer, T, 2012) |
| "In this enriched design study, 1,160 opioid-experienced patients with chronic, moderate to severe low back pain entered an open-label run-in period; 660 demonstrated analgesic benefit from and tolerability to buprenorphine transdermal system 20 mcg/hour (BTDS 20) treatment and were randomized to receive either BTDS 20, BTDS 5 mcg/hour (BTDS 5), or the active control (immediate release oxycodone 40-mg/day) during an 84-day double-blind phase." | 9.15 | Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. ( Hale, M; Landau, C; Munera, C; Ripa, S; Steiner, D, 2011) |
| "Local anesthetics, such as the 5% transdermal lidocaine patch (5LP), have been frequently used in the treatment of musculoskeletal pain, especially chronic low back pain (CLBP)." | 9.05 | The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review. ( Felix, ER; Klass, S; Santana, JA, 2020) |
| " Results from a network meta-analysis of non-enriched designs (eight trials), using trials versus placebo and trials versus morphine for indirect comparisons, indicated that transdermal fentanyl, in comparison with transdermal buprenorphine, showed significantly more nausea (odds ratio [OR] 4." | 8.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "Efficacy and tolerability of buprenorphine patches was demonstrated in chronic pain patients, regardless of age, supporting the conclusion that no age-related dose adjustment of transdermal buprenorphine is needed." | 7.80 | Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. ( Augustini, BG; Berggren, AC; Karlsson, J; Söderström, A, 2014) |
| " The use of transdermal buprenorphine for chronic pain management is discussed." | 7.79 | Buprenorphine for chronic pain. ( Calderon, R; Copenhaver, D, 2013) |
| "Six-months analysis of non-interventionally collected observation data of effectiveness of long-term treatment with low-dose 7-day buprenorphine transdermal patch in elderly patients with chronic pain." | 7.79 | [Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life]. ( Müller-Schwefe, GH; Uberall, MA, 2013) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 6.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| "Background and aims Chronic pain is a life altering condition and common among elderly persons." | 5.42 | Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights. ( Dahm, P; Norrlid, H; Tennvall, GR, 2015) |
| "We examined the effectiveness and tolerability of transdermal buprenorphine (TDB) treatment in real-world setting in Asian patients with musculoskeletal pain." | 5.24 | Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. ( Bin, SI; Chan, SK; Chung, CK; In, Y; Kim, H; Lichauco, JJ; Mok, CC; Moon, H; Moon, YW; Ng, TK; Penserga, EG; Shin, DA; Yoon, DH; You, D, 2017) |
| "This study examines the efficacy of the buprenorphine transdermal system (BTDS) for reducing the interference of pain on physical and emotional functioning associated with chronic low back pain (CLBP)." | 5.20 | Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. ( Lynch, SY; Miller, K; Munera, C; Pergolizzi, JV; Raffa, R; Ripa, SR; Wen, W; Yarlas, A, 2015) |
| "To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks." | 5.17 | Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. ( Brennan, MJ; Dain, B; Lynch, SY; Miller, K; Ripa, SR; Wen, W; Yarlas, A, 2013) |
| "The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients." | 5.16 | Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. ( Apkarian, AV; Baliki, MN; Chanda, ML; Hashmi, JA; Huang, L; Parks, EL; Schnitzer, T, 2012) |
| "In this enriched design study, 1,160 opioid-experienced patients with chronic, moderate to severe low back pain entered an open-label run-in period; 660 demonstrated analgesic benefit from and tolerability to buprenorphine transdermal system 20 mcg/hour (BTDS 20) treatment and were randomized to receive either BTDS 20, BTDS 5 mcg/hour (BTDS 5), or the active control (immediate release oxycodone 40-mg/day) during an 84-day double-blind phase." | 5.15 | Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. ( Hale, M; Landau, C; Munera, C; Ripa, S; Steiner, D, 2011) |
| "Local anesthetics, such as the 5% transdermal lidocaine patch (5LP), have been frequently used in the treatment of musculoskeletal pain, especially chronic low back pain (CLBP)." | 5.05 | The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review. ( Felix, ER; Klass, S; Santana, JA, 2020) |
| "Buprenorphine is a lipid-soluble pharmaceutic used in the management of chronic pain." | 4.91 | Buprenorphine: revisiting the efficacy of transdermal delivery system. ( Barnett, CJ; Bergese, SD; Kamar, N; Kitzmiller, JP; Luzum, JA; Mikulik, E; Steiner, NS; Stoicea, N, 2015) |
| " Results from a network meta-analysis of non-enriched designs (eight trials), using trials versus placebo and trials versus morphine for indirect comparisons, indicated that transdermal fentanyl, in comparison with transdermal buprenorphine, showed significantly more nausea (odds ratio [OR] 4." | 4.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "Buprenorphine is a partial mu-opioid agonist available as a transdermal patch for use in patients with chronic pain." | 4.12 | Application Site Reactions from the Buprenorphine Transdermal Patch: A Case Series. ( Fudin, J; Mendoza, K; Meyer-Junco, L; Rea, B, 2022) |
| " This study compares rates of poison center calls categorized as intentional abuse, suspected suicidal intent or fatality for the 7-day buprenorphine transdermal system/patch (BTDS) with other extended-release and long-acting (ER/LA) opioids indicated for chronic pain." | 3.85 | Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. ( Coplan, PM; Harikrishnan, V; Perkel, C; Sessler, NE; Singh, R, 2017) |
| "Efficacy and tolerability of buprenorphine patches was demonstrated in chronic pain patients, regardless of age, supporting the conclusion that no age-related dose adjustment of transdermal buprenorphine is needed." | 3.80 | Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. ( Augustini, BG; Berggren, AC; Karlsson, J; Söderström, A, 2014) |
| "To characterize the profile of application site reactions (ASRs) for patients treated with the buprenorphine transdermal system (BTDS) in chronic pain studies." | 3.79 | Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. ( Lynch, SY; Maibach, H; Munera, C; Ripa, SR; Swanton, R; Wen, W, 2013) |
| " The use of transdermal buprenorphine for chronic pain management is discussed." | 3.79 | Buprenorphine for chronic pain. ( Calderon, R; Copenhaver, D, 2013) |
| "Six-months analysis of non-interventionally collected observation data of effectiveness of long-term treatment with low-dose 7-day buprenorphine transdermal patch in elderly patients with chronic pain." | 3.79 | [Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life]. ( Müller-Schwefe, GH; Uberall, MA, 2013) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 2.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| " Various retrospective studies comparing dosage changes of buprenorphine and fentanyl patches in persistent pain patients have been completed; however, no long-term prospective, randomized, clinical study has compared the effectiveness of these patches." | 2.78 | A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. ( Chowdhury, S; Mitra, F; Shelley, M; Williams, G, 2013) |
| "Many patients experience acute or chronic pain." | 2.52 | [Certain opioids can preferably be administered transdermally]. ( Holmgaard, R; Jensen, NM; Nielsen, JB; Sørensen, JA, 2015) |
| "Neuropathic pain is a complex condition that is difficult to control and has a high impact on quality of life." | 1.56 | 8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain. ( Barbosa, P; Gomes, A; Goncalves, D; Rebelo, V, 2020) |
| "Tramadol has a higher risk of fractures than some other opioid analgesics used to treat moderate-to-severe pain and, in the model described here, we investigate the cost effectiveness of transdermal buprenorphine treatment compared with tramadol in a high-risk population." | 1.43 | Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine. ( Akehurst, R; Dunlop, W; Hirst, A; Hirst, M; Knight, C, 2016) |
| "Background and aims Chronic pain is a life altering condition and common among elderly persons." | 1.42 | Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights. ( Dahm, P; Norrlid, H; Tennvall, GR, 2015) |
| " Initial BTDS dosing strength, receipt of approved initial BTDS dose per the FPI, and concomitant medications were assessed in the post-index 6 month period." | 1.40 | US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. ( Ben-Joseph, R; Chang, CL; Hess, G; Pergolizzi, JV, 2014) |
| "Buprenorphine is a chemically synthesized opioid characterized as the partial mu agonist and kappa antagonist, and transdermal buprenorphine patch will be considered useful as a strong analgesic with fewer psychological side effects in the treatment of chronic non-cancer pain." | 1.39 | [Buprenorphine transdermal patch (Norspan tape)]. ( Hamaguchi, S; Ikeda, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 41 (91.11) | 24.3611 |
| 2020's | 4 (8.89) | 2.80 |
| Authors | Studies |
|---|---|
| Kapoor, H | 1 |
| Gupta, E | 1 |
| Sood, A | 1 |
| Meyer-Junco, L | 1 |
| Rea, B | 1 |
| Mendoza, K | 1 |
| Fudin, J | 1 |
| Santana, JA | 1 |
| Klass, S | 1 |
| Felix, ER | 1 |
| Noe, MH | 1 |
| Shin, DB | 1 |
| Wehner, MR | 1 |
| Margolis, DJ | 1 |
| Gelfand, JM | 1 |
| Goncalves, D | 1 |
| Rebelo, V | 1 |
| Barbosa, P | 1 |
| Gomes, A | 1 |
| Yoon, DH | 1 |
| Bin, SI | 1 |
| Chan, SK | 1 |
| Chung, CK | 1 |
| In, Y | 1 |
| Kim, H | 1 |
| Lichauco, JJ | 1 |
| Mok, CC | 1 |
| Moon, YW | 1 |
| Ng, TK | 1 |
| Penserga, EG | 1 |
| Shin, DA | 1 |
| You, D | 1 |
| Moon, H | 1 |
| Norrlid, H | 1 |
| Dahm, P | 1 |
| Tennvall, GR | 1 |
| Chung, CP | 1 |
| Dupont, WD | 1 |
| Murray, KT | 1 |
| Hall, K | 1 |
| Stein, CM | 1 |
| Ray, WA | 1 |
| Davis, MP | 1 |
| Pasternak, G | 1 |
| Behm, B | 1 |
| Luchting, B | 1 |
| Azad, SC | 1 |
| Taylor, RG | 1 |
| Budhram, A | 1 |
| Lee, DH | 1 |
| Mirsattari, SM | 1 |
| Wen, W | 3 |
| Lynch, SY | 3 |
| Munera, C | 3 |
| Swanton, R | 1 |
| Ripa, SR | 3 |
| Maibach, H | 1 |
| Martini, CH | 1 |
| Yassen, A | 1 |
| Krebs-Brown, A | 1 |
| Passier, P | 1 |
| Stoker, M | 1 |
| Olofsen, E | 1 |
| Dahan, A | 1 |
| Ibuki, T | 1 |
| Hamaguchi, S | 1 |
| Ikeda, T | 1 |
| Collopy, KT | 1 |
| Kivlehan, SM | 1 |
| Snyder, SR | 1 |
| Weekes, G | 1 |
| O'Brien, J | 1 |
| Murphy, K | 1 |
| Keavney, J | 1 |
| Pollard, V | 1 |
| Chapman, CR | 1 |
| Bradshaw, DH | 1 |
| Calderon, R | 1 |
| Copenhaver, D | 1 |
| Karlsson, J | 1 |
| Söderström, A | 1 |
| Augustini, BG | 1 |
| Berggren, AC | 1 |
| Pergolizzi, JV | 3 |
| Ben-Joseph, R | 2 |
| Chang, CL | 2 |
| Hess, G | 2 |
| Uberall, MA | 1 |
| Müller-Schwefe, GH | 1 |
| López-Pérez, FJ | 1 |
| Mínguez-Martí, A | 1 |
| Vicario-Sánchez, E | 1 |
| Pastor-Clérigues, A | 1 |
| Sanfeliu-García, J | 1 |
| Ortega-García, MP | 1 |
| Dankiewicz, EH | 1 |
| Haddox, JD | 1 |
| Yarlas, A | 2 |
| Miller, K | 2 |
| Raffa, R | 1 |
| Jensen, NM | 1 |
| Holmgaard, R | 1 |
| Nielsen, JB | 1 |
| Sørensen, JA | 1 |
| Hirst, A | 1 |
| Knight, C | 1 |
| Hirst, M | 1 |
| Dunlop, W | 1 |
| Akehurst, R | 1 |
| Kitzmiller, JP | 1 |
| Barnett, CJ | 1 |
| Steiner, NS | 1 |
| Stoicea, N | 1 |
| Kamar, N | 1 |
| Luzum, JA | 1 |
| Mikulik, E | 1 |
| Bergese, SD | 1 |
| Rascol, O | 1 |
| Zesiewicz, T | 1 |
| Chaudhuri, KR | 1 |
| Asgharnejad, M | 1 |
| Surmann, E | 1 |
| Dohin, E | 1 |
| Nilius, S | 1 |
| Bauer, L | 1 |
| Oppliger, M | 1 |
| Mauermann, E | 1 |
| Ruppen, W | 1 |
| Kawai, K | 1 |
| Yoshizawa, K | 1 |
| Fujie, M | 1 |
| Kobayashi, H | 1 |
| Ogawa, Y | 1 |
| Yajima, T | 1 |
| Romualdi, P | 1 |
| Santi, P | 1 |
| Candeletti, S | 1 |
| Coplan, PM | 1 |
| Sessler, NE | 1 |
| Harikrishnan, V | 1 |
| Singh, R | 1 |
| Perkel, C | 1 |
| Trist, AJ | 1 |
| Sahota, H | 1 |
| Williams, L | 1 |
| Steiner, D | 1 |
| Hale, M | 1 |
| Ripa, S | 1 |
| Landau, C | 1 |
| Rastogi, R | 1 |
| Swarm, RA | 1 |
| Patel, TA | 1 |
| Plosker, GL | 1 |
| Lyseng-Williamson, KA | 1 |
| Wolff, RF | 1 |
| Aune, D | 1 |
| Truyers, C | 1 |
| Hernandez, AV | 1 |
| Misso, K | 1 |
| Riemsma, R | 1 |
| Kleijnen, J | 1 |
| Hashmi, JA | 1 |
| Baliki, MN | 1 |
| Huang, L | 1 |
| Parks, EL | 1 |
| Chanda, ML | 1 |
| Schnitzer, T | 1 |
| Apkarian, AV | 1 |
| Miotto, K | 1 |
| Kaufman, A | 1 |
| Kong, A | 1 |
| Jun, G | 1 |
| Schwartz, J | 1 |
| Steunebrink, M | 1 |
| Zwerver, J | 1 |
| Brandsema, R | 1 |
| Groenenboom, P | 1 |
| van den Akker-Scheek, I | 1 |
| Weir, A | 1 |
| López Ramírez, E | 1 |
| Mitra, F | 1 |
| Chowdhury, S | 1 |
| Shelley, M | 1 |
| Williams, G | 1 |
| Dain, B | 1 |
| Brennan, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid [NCT01961271] | Phase 4 | 114 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [NCT01276431] | Phase 4 | 102 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-release Versus BTDS 5 in Subjects With Moderate to Severe Low Back Pain[NCT00313014] | Phase 3 | 660 participants (Actual) | Interventional | 2004-02-29 | Terminated (stopped due to Terminated early due to administrative reasons unrelated to efficacy or safety.) | ||
| Mind-body Treatments for Chronic Back Pain[NCT03294148] | 151 participants (Actual) | Interventional | 2017-08-07 | Completed | |||
| Randomized, Placebo-controlled Crossover Trial Evaluating Topical Lidocaine Patch(es) for Mechanical Neck Pain.[NCT04378959] | 76 participants (Actual) | Interventional | 2021-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary efficacy outcome analysis is the pre- and post-intervention change in BS-11 pain score. The reduction in scores were calculated by subtracting the post-intervention score from the baseline score.~BS-11 is known as Box scale-11; it is an 11-point scale measuring pain intensity. It ranges from 0 to 10, whereby 0 represents no pain and 10 represents the worst imaginable pain. Subjects selected a number based on the pain intensity they were feeling at that time." (NCT01961271)
Timeframe: Maximum 17 weeks starting from enrolment
| Intervention | units on a scale (Mean) |
|---|---|
| Buprenorphine Transdermal Patch | 2.7 |
(NCT01961271)
Timeframe: From time of enrolment to Visit 6 (ie. up to119 days from enrolment)
| Intervention | participants (Number) |
|---|---|
| Buprenorphine Transdermal Patch | 3 |
Daily use of breakthrough pain medication from visits 1-6, assessed from patient diaries. (NCT01961271)
Timeframe: Approximately 17 weeks starting from enrolment
| Intervention | participants (Number) |
|---|---|
| Buprenorphine Transdermal Patch | 26 |
Side effects of the transdermal patch treatment will be analysed. (NCT01961271)
Timeframe: From time of enrolment up to 7 days after completion / discontinuation visit (up to 140 days)
| Intervention | participants (Number) |
|---|---|
| Buprenorphine Transdermal Patch | 89 |
"Pre-intervention: Visit 1 Post-intervention: Visit 6~There are 5 dimensions in the EQ5D-3L questionnaire answered by the subjects, classified into 5 categories here:~Mobility -- change in % of subjects who have no problem in walking around Self-care -- change in % of subjects who have no problem in self-care Usual activities -- change in % of subjects who have no problem with performing their usual activities Pain/ discomfort -- change in % of subjects who do not experience pain or discomfort Anxiety/ depression -- change in % of subjects who do not feel anxious or depressed" (NCT01961271)
Timeframe: approximately 17 weeks starting from enrolment
| Intervention | percentage of subjects (Number) | ||||
|---|---|---|---|---|---|
| Mobility | Self-care | Usual Activities | Pain/Discomfort | Anxiety/ Depression | |
| Buprenorphine Transdermal Patch | 25.8 | 20.2 | 19.4 | 14.3 | 18 |
"The overall assessment of the change in pain intensity from baseline is measured at Visit 6.~Physician's Global Impression of Change scale: Investigator's opinion on a scale of 1 to 7 where 1 is very much improved and 7 is very much worse Patient's Global Impression of Change scale: Subject's opinion on a scale of 1 to 7 where 1 is very much improved and 7 is very much worse" (NCT01961271)
Timeframe: At visit 6 (anywhere between Day 91 to 119 after enrolment depending on how long titration took)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Physician Impression | Patient Impression | |
| Buprenorphine Transdermal Patch | 2.62 | 2.66 |
The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase (NCT00313014)
Timeframe: Double-blind phase (84 days)
| Intervention | tablets (Mean) |
|---|---|
| Double-blind BTDS 5 | 3.8 |
| Double-blind BTDS 20 | 3.3 |
| Double-blind Oxycodone Immediate-Release | 3.5 |
"Subjects were evaluated during the double-blind phase for average pain over the last 24 hours prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)" (NCT00313014)
Timeframe: Last 24 hours score at weeks 4, 8, 12 of the double-blind phase
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Screening | Prerandomization | Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 6.46 | 2.91 | 3.40 | 3.35 | 3.35 |
| Double-blind BTDS 5 | 6.36 | 2.84 | 3.79 | 3.83 | 4.02 |
| Double-blind Oxycodone Immediate-Release | 6.46 | 2.74 | 3.14 | 3.24 | 3.26 |
"The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes.~The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)" (NCT00313014)
Timeframe: Weeks 4, 8, 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 33.04 | 34.27 | 33.06 |
| Double-blind BTDS 5 | 34.80 | 35.69 | 36.30 |
| Double-blind Oxycodone Immediate-Release | 30.79 | 31.64 | 32.96 |
"The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath).~Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance." (NCT00313014)
Timeframe: Weeks 4, 8, 12 of the double-blind phase
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 34.65 | 35.69 | 33.65 |
| Double-blind BTDS 5 | 40.67 | 42.28 | 40.85 |
| Double-blind Oxycodone Immediate-Release | 38.10 | 39.17 | 41.60 |
1-week average pain intensity, 0 - 10 numerical rating scale, where a higher score indicates more pain. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 1.18 |
| Placebo | 2.84 |
| Usual Care | 3.13 |
Questionnaire to rate negative affect, scores range from 5 - 25, with a higher score meaning a stronger negative affect (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 8.30 |
| Placebo | 7.70 |
| Usual Care | 8.19 |
Back pain disability questionnaire measured on a scale of 0-100. A higher score indicates a higher severity of disability. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 10.14 |
| Placebo | 19.00 |
| Usual Care | 20.68 |
Questionnaire used to help quantify an individual's pain experience. Measured 0-52. A higher score means a higher level of catastrophizing. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 8.30 |
| Placebo | 7.70 |
| Usual Care | 8.19 |
Post-treatment-only outcome measure depicting a patient's subjective rating of overall improvement. Score ranges from 1-7 with a higher score indicating a higher level of change and improvement (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 6.14 |
| Placebo | 3.61 |
| Usual Care | 2.06 |
Questionnaire to rate positive affect, scores range from 5 - 25, a higher score means stronger affect (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 17.89 |
| Placebo | 15.20 |
| Usual Care | 14.98 |
Questionnaire measuring anger (5 items) with a score range of 5-25. Higher scores indicate a higher severity of anger. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 9.52 |
| Placebo | 9.89 |
| Usual Care | 10.45 |
Questionnaire measuring anxiety (8 items). Scores range from 8-40 with a higher score meaning more severe levels of fear, anxious misery, hyperarousal, and somatic symptoms related to arousal. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 15.02 |
| Placebo | 13.89 |
| Usual Care | 14.11 |
Questionnaire measuring sleep disturbance (8 items). Scores range from 8-40. Higher scores indicate higher levels of sleep disturbance (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 17.73 |
| Placebo | 20.50 |
| Usual Care | 20.89 |
Questionnaire measuring depression (8 items). Scores range from 8-32. A higher score indicates higher levels of depressive symptoms (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 12.23 |
| Placebo | 11.75 |
| Usual Care | 11.81 |
Questionnaire used to assess the subjective rating of kinesiophobia or fear of movement. Scores range from 11-44 with higher scores indicating greater fear of pain, movement, and injury. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 16.41 |
| Placebo | 22.16 |
| Usual Care | 22.51 |
Questionnaire used to assess daily drinking (number of drinks consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Drinks (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 11.63 |
| Placebo | 12.88 |
| Usual Care | 8.02 |
Questionnaire used to assess daily cannabis use (number of grams consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Grams of cannabis (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 6.76 |
| Placebo | 3.31 |
| Usual Care | 1.49 |
Questionnaire used to assess daily opioid use (number of pills consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Opioid pills (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 1.29 |
| Placebo | 0.36 |
| Usual Care | 1.77 |
Post-treatment-only outcome measure depicting the patient's satisfaction with the treatment. Measured 0 - 100. A higher score means higher satisfaction with treatment/ (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 92.40 |
| Placebo | 57.61 |
| Usual Care | 36.86 |
10 reviews available for oxybutynin and Chronic Pain
| Article | Year |
|---|---|
Chronic pelvic ischemia: etiology, pathogenesis, clinical presentation and management.
Topics: Aged; Animals; Atherosclerosis; Calcium; Cell Hypoxia; Chronic Pain; Disease Models, Animal; Estroge | 2014 |
The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review.
Topics: Anesthetics, Local; Chronic Pain; Humans; Lidocaine; Low Back Pain; Randomized Controlled Trials as | 2020 |
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.
Topics: Administration, Sublingual; Analgesics, Opioid; Animals; Buprenorphine; Chemistry, Pharmaceutical; C | 2018 |
Pain therapy for the elderly patient: is opioid-free an option?
Topics: Administration, Topical; Age Factors; Aged; Aging; Analgesics, Non-Narcotic; Analgesics, Opioid; Cap | 2019 |
[Certain opioids can preferably be administered transdermally].
Topics: Acute Pain; Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Anti-Inflammatory A | 2015 |
Buprenorphine: revisiting the efficacy of transdermal delivery system.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Drug Delivery Systems; Humans; Transdermal Patch | 2015 |
Alghedon Fentanyl Transdermal System.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Fentanyl; | 2017 |
Case scenario: opioid association with serotonin syndrome: implications to the practitioners.
Topics: Analgesics, Opioid; Antidepressive Agents, Tricyclic; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhi | 2011 |
Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Delayed-Action Preparations; Dose-Response Relation | 2012 |
Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Fentanyl; Human | 2012 |
9 trials available for oxybutynin and Chronic Pain
| Article | Year |
|---|---|
Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Hon | 2017 |
A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia.
Topics: Aged; Aged, 80 and over; Capsaicin; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Ma | 2013 |
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Double-Blind Meth | 2015 |
A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
Topics: Aged; Chronic Pain; Dopamine Agonists; Double-Blind Method; Female; Humans; Internationality; Male; | 2016 |
Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Chronic Pain; Double-Blind Method; Fem | 2011 |
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study.
Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne | 2012 |
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study.
Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne | 2012 |
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study.
Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne | 2012 |
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study.
Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne | 2012 |
Topical glyceryl trinitrate treatment of chronic patellar tendinopathy: a randomised, double-blind, placebo-controlled clinical trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics; Chronic Pain; Double-Blind Method; Humans; | 2013 |
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Disease; Chronic Pain; | 2013 |
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Dose-Response Rel | 2013 |
26 other studies available for oxybutynin and Chronic Pain
| Article | Year |
|---|---|
Application Site Reactions from the Buprenorphine Transdermal Patch: A Case Series.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Transdermal Patc | 2022 |
Opioid prescribing in adults with and without psoriasis.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Chronic Pain; Dermatologic Agents; Drug Presc | 2020 |
8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Capsaicin; Child; Chronic Pain; Female; Humans; Male; Mi | 2020 |
Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Pain; Clinical Trials as Topic; | 2015 |
Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Drug Overdose; Female; F | 2019 |
Opioid-associated amnestic syndrome observed with fentanyl patch use.
Topics: Administration, Cutaneous; Amnesia; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Midd | 2019 |
Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis.
Topics: Administration, Cutaneous; Aged; Buprenorphine; Chronic Pain; Clinical Trials, Phase III as Topic; D | 2013 |
[Transdermal fentanyl patch for the treatment of chronic intractable pain].
Topics: Analgesics, Opioid; Chronic Pain; Fentanyl; Humans; Pain, Intractable; Transdermal Patch | 2013 |
[Buprenorphine transdermal patch (Norspan tape)].
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Pain, Intractable; Transdermal Patch | 2013 |
An EMS guide to chronic pain.
Topics: Analgesics, Opioid; Anticonvulsants; Biological Availability; Chronic Pain; Drug Therapy, Combinatio | 2013 |
Qutenza patch--our early experience.
Topics: Activities of Daily Living; Analgesics; Capsaicin; Chronic Pain; Humans; Neuralgia; Pain Measurement | 2013 |
Only modest long-term opioid dose escalation occurs over time in chronic nonmalignant pain management.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; | 2013 |
Buprenorphine for chronic pain.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Opiate Substitution Treatment; Opioid-Relat | 2013 |
Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Human | 2014 |
Predicting medication persistence to buprenorphine transdermal system.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammat | 2015 |
US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Pain; Databas | 2014 |
[Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anxiety; Buprenorphine; Chronic Pain; Depressio | 2013 |
[Clinical experience in opioid switch for noncancer chronic pain treatment].
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Aged; Aged, 80 and over; Analgesia, Epidural; Analges | 2014 |
Clarification on transdermal buprenorphine.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Transdermal Patch | 2014 |
Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine.
Topics: Aged; Aged, 80 and over; Buprenorphine; Chronic Pain; Cost-Benefit Analysis; Drug Costs; Female; Fra | 2016 |
Are transdermal opioids contraindicated in patients at risk of suicide?: An underappreciated problem.
Topics: Analgesics, Opioid; Autopsy; Chronic Pain; Death, Sudden, Cardiac; Female; Fentanyl; Humans; Middle | 2016 |
Use of Fentanyl Patch for Treatment of Moderate-to-severe Chronic Noncancer Pain: Postmarketing Surveillance of Medical Practice in Japan Using a Risk Minimization Action Plan.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Japan; Male; Middle Aged; O | 2017 |
Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Cause of Death; Chronic Pain; Coh | 2017 |
Not so patchy story of attempted suicide…leading to 24 hours of deep sleep and survival!
Topics: Aged; Analgesics, Opioid; Back Pain; Chronic Pain; Drug Overdose; Female; Fentanyl; Humans; Suicide, | 2017 |
Managing co-occurring substance use and pain disorders.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Child; Chronic Pain; Diagnostic and | 2012 |
Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience.
Topics: Acute Pain; Aged; Aged, 80 and over; Anesthetics, Local; Chronic Pain; Female; Humans; Lidocaine; Ma | 2013 |